HC Wainwright Has Negative Forecast for DYN FY2026 Earnings

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Stock analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of Dyne Therapeutics in a report released on Friday, November 6th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings per share of ($3.83) for the year, down from their prior forecast of ($3.82). HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q4 2026 earnings at ($0.95) EPS, Q1 2027 earnings at ($0.91) EPS, FY2027 earnings at ($3.42) EPS, FY2028 earnings at ($2.15) EPS and FY2029 earnings at ($0.84) EPS.

DYN has been the topic of several other research reports. Oppenheimer downgraded shares of Dyne Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $40.00 to $15.00 in a research report on Wednesday, October 28th. Chardan Capital reaffirmed a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a report on Wednesday, September 30th. Piper Sandler reiterated an “overweight” rating and set a $47.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Thursday, October 15th. Finally, Cantor Fitzgerald reissued a “buy” rating on shares of Dyne Therapeutics in a report on Wednesday, September 30th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.29.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock opened at $18.62 on Tuesday. The firm has a market capitalization of $3.48 billion, a P/E ratio of -5.13 and a beta of 1.22. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. The company has a 50 day moving average price of $17.57 and a 200 day moving average price of $19.34. Dyne Therapeutics has a 52 week low of $14.00 and a 52 week high of $27.31.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.15). During the same period last year, the business earned ($0.76) earnings per share.

Insider Activity

In other Dyne Therapeutics news, Director Brian S. Posner purchased 2,500 shares of the business’s stock in a transaction that occurred on Friday, October 2nd. The stock was purchased at an average price of $16.00 per share, for a total transaction of $40,000.00. Following the purchase, the director directly owned 27,000 shares in the company, valued at approximately $432,000. This trade represents a 10.20% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jason P. Rhodes sold 2,160,516 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the transaction, the director directly owned 428,946 shares of the company’s stock, valued at $10,723,650. The trade was a 83.43% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,598,706 shares of company stock worth $65,432,671 over the last 90 days. Company insiders own 9.46% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Dyne Therapeutics during the 2nd quarter worth approximately $275,500,000. Jupiter Topco LLC purchased a new position in shares of Dyne Therapeutics during the 2nd quarter valued at approximately $266,634,000. Perceptive Advisors LLC grew its stake in Dyne Therapeutics by 34.2% in the 1st quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company’s stock valued at $84,646,000 after acquiring an additional 1,189,895 shares during the period. Orbimed Advisors LLC grew its stake in Dyne Therapeutics by 32.5% in the 1st quarter. Orbimed Advisors LLC now owns 2,917,884 shares of the company’s stock valued at $52,901,000 after acquiring an additional 715,700 shares during the period. Finally, Bank of America Corp DE purchased a new stake in Dyne Therapeutics in the 2nd quarter worth $49,604,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue.

The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy.